GCG and type 2 diabetes mellitus: Another point to consider is that if any cardiovascular benefit exists, then the optimal dosing and administration of GLP-1 agonists in different populations with a spectrum of different co-morbidities in addition to type 2 diabetes mellitus is still an unexplored path.